Entera Bio Ltd (ENTX)

Entera Bio Ltd. is a clinical-stage biotechnology company focused on developing oral peptide and protein replacement therapies in Israel and international markets. Its pipeline includes EB613, an oral teriparatide candidate that has completed Phase II testing in osteoporosis and Phase I testing in stress fractures, as well as EB612, a tablet-based peptide replacement therapy in Phase I trials for hypoparathyroidism. The company is also advancing EB618, a GLP-1/glucagon dual agonist peptide being studied for obesity, metabolic, and fibrotic disorders, and GLP-2, which is in Phase I development for short bowel syndrome and conditions associated with mucosal inflammation and nutrient malabsorption. Entera Bio also has a collaboration with OPKO Biologics, Inc. covering preclinical and clinical development of LA-PTH and an oral GLP-1/glucagon dual agonist peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.